右美托咪定用于眼科手术局麻强化的临床研究
|
摘要
右美托咪定是一种新型、高选择性α_2肾上腺素能受体激动剂,具有镇静镇痛、抗焦虑、稳定血流动力学、无呼吸抑制、术后遗忘等作用。因此在很多临床领域都得到广泛应用,尤其在麻醉辅助用药方面,为麻醉医生提供了一种新的选择。然而有关右美托咪定在眼科手术中应用的研究甚少。
目的:评价右美托咪定在眼科手术局麻强化中镇静、镇痛、维持血流动力学稳定、诱导遗忘等效果。
方法:选择择期行眼科手术的局麻强化患者100例为研究对象,其中行玻璃体切除术患者50例,小梁切除术患者50例。美国麻醉医师协会分级Ⅰ～Ⅱ级,年龄16～80岁,体重35～80 kg。将研究对象分为两组,实验组(右美托咪定组)和对照组(安慰剂组),每组各50例,两种患者各25例。实验组患者手术开始前10min给予右美托咪定负荷剂量0.5μg/kg,输注时间大于10 min,之后以0.5μg/(kg*h)进行维持;对照组给予等体积的生理盐水。手术医生用2%利多卡因进行球周浸润麻醉时,两组患者均给予静脉注射半量芬氟合剂(芬太尼50μg +氟哌利多2.5mg)。记录手术开始前10mim(T_0)、开始时(T_1)、开始后10min(T_2)、开始后30min(T_3)、开始后60min(T_4)、手术结束时(T_5)两组患者的呼吸频率、心率、收缩压、舒张压、平均动脉压、VAS评分和Ramsay评分,同时记录术中合作程度、术后遗忘程度和术后不良反应。采用SPSS 13.0统计软件进行统计分析。
结果:
1.实验组和对照组患者的年龄、性别、体重、手术时间差异无统计学意义,两组研究对象具有可比性。
2. Ramsay评分在T_0时两组间的差异无统计学意义,而在T_1～T_5时差异显著,且实验组的镇静评分显著高于对照组。
3. VAS评分在T_0时两组间的差异无统计学意义,而在T_1～T_5时差异显著,且实验组镇痛评分显著低于对照组。
4. T_0时刻实验组和对照组患者的SBP无统计学差异,而HR、DBP、MAP差异显著,且实验组显著低于对照组;T_1时刻实验组和对照组的HR、DBP、MAP无统计学差异,而SBP差异显著,且实验组显著低于对照组;T_2～T_5时刻HR、SBP、DBP、MAP在两组间差异显著,且实验组均低于对照组。
5. RR在T_0时刻两组间的差异无统计学意义,而在T_1～T_5时刻差异显著,且实验组患者的RR显著低于对照组。
6.患者术中合作程度在实验组和对照组间差异无统计学意义。术后遗忘程度在两组之间的差异显著,具有统计学意义,且实验组中完全遗忘者所占的比例(68%)显著高于对照组(0%)。
7.恶心、呕吐、呼吸抑制、心动过缓、躁动和嗜睡的发生率在实验组和对照组间的差异不具有统计学意义。
结论:
1.在眼科局麻手术中应用右美托咪定,可为患者提供满意舒适的镇静,且不降低术中患者的合作程度。
2.右美托咪定具有镇痛作用,能够增加眼科局麻手术患者对疼痛的耐受性。
3.右美托咪定能够维持血流动力学的稳定。
4.右美托咪定能够消除眼科局麻手术患者对麻醉和手术操作等的不良记忆,具有一定的顺行性遗忘作用。
5.眼科局麻手术中右美托咪定的应用不会增加恶心、呕吐、呼吸抑制、心动过缓、躁动和嗜睡等不良反应的发生率。
Dexmedetomidine is a new type of high selectiveα_2-adrenergic receptor agonists, which has sedative, analgesic and anxiolytic effects, can maintain hemodynamic stability, has no respiratory depression, amnesia after surgery and son on. Therefore it has applications in many fields of clinical medicine, especially as an adjuvant in anesthesia, providing the anesthesiologist a new choice. However, there is little research about giving the dexmedetomidine in ophthalmic surgery.
Objective: Evaluate the effects of sedative, analgesic, maintaining hemodynamic stability and forgotten, when dexmedetomidine was applicated to patients in ophthalmic surgery under local anesthesia.
Methods: Select 100 patients who were undergoing ophthalmic surgery with local anesthesia as the research object, 50 patients with vitrectomy, 50 patients with trabeculectomy. All the patients were ASAⅠ-Ⅱ, aged 16-80 years, weight 35-80 kg, of Which 50 patients with vitrectomy and the other 50 ones with trabeculectomy. Patients were divided into two groups, the experimental group(dexmedetomidine group) and control group (placebo group). Each group has 50 patients. The patients of the experimental group before surgery 10 min were given dexmedetomidine loading dose of 0.5μg/kg, the infusion time is greater than 10 min, followed by 0.5μg /(kg·h) for maintenance; control group received an equal volume of physiological salt. When the surgeon with 2% lidocaine for peribulbar anesthesia, the two groups of patients were given intravenous injection of half the amount of fentany-droperidol mixture (fentanyl 50μg+droperidol 2.5mg). Routine monitoring and recording the respiratory rate (RR), heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), main arterial blood pressure(MAP), VAS score and Ramsay score of patients in each group at 10 min before surgery (T_0), the time of starting surgery(T_1), 10 min after the start of surgery(T_2), 30 min after the start of surgery(T_3), 60 min after the start of surgery(T_4) and at the end of surgery (T_5), at the same time, recording the level of cooperation between intraoperative, the degree of surgical forgotten and postoperative adverse. Use SPSS 13.0 statistical software for statistical processing.
Results:
1. The difference between experimental group and control group in age, gender, weight and operation tine was not statistically significant. The two group had comparability.
2. Ramsay score was not significantly different between two groups at T_0, while was at T_1～T_5. Furthermore, Ramsay score in experimental group was significantly higher than control group.
3. VAS score was not significantly different between two groups at T_0, while was at T_1～T_5. Furthermore, VAS score in experimental group was significantly lower than control group.
4. At the time of T_0, SBP was not significantly different between experimental group and control group, while HR, DBP and MAP were. Furthermore, HR, DBP and MAP in experimental group were significantly lower than control group. At the time of T_1, HR, DBP and MAP were not significantly different between two groups, while SBP was. Furthermore, SBP in experimental group was significantly lower than control group. At the time of T_1～T_5, HR, SBP, DBP and MAP were significantly different between two groups, and all of them in experimental group were significantly lower than control group.
5. RR was not significantly different between two groups at T_0, while was at T_1～T_5. Furthermore, RR in experimental group was significantly higher than control group.
6. Cooperation degree of patients was not significantly different between experimental group and control group during surgery. The degree of postoperative forgotten was significantly different between two groups, and the rate of completely forgotten in experimental group (68%) was statistically higher than control group (0%).
7. The number of cases of nausea, vomiting, respiratory depression, bradycardia, restlessness and drowsiness were not significantly different between experimental group and control group.
Conclusion:
1. The application of dexmedetomidine in ophthalmic surgery under local anesthesia could make the Ramsay score of experimental group significantly higher, with providing comfortable calm for patients and not decreasing the cooperation degree during surgery.
2. Dexmedetomidine had analgesic effect, which can increase tolerability to pain for patients with ophthalmic surgery under local anesthesia.
3. Dexmedetomidine could maintain hemodynamic stability.
4. Dexmedetomidine could eliminate poor memory appearing because of anesthesia and operation of surgery in ophthalmic surgery under local anesthesia. Therefore, dexmedetomodine had a certain line of the forgotten role.
5. The application of dexmedetomidine in ophthalmic surgery under local anesthesia will not produce nausea, vomiting, respiratory inhibition, bradycardia, restlessness and drowsiness.
目的:评价右美托咪定在眼科手术局麻强化中镇静、镇痛、维持血流动力学稳定、诱导遗忘等效果。
方法:选择择期行眼科手术的局麻强化患者100例为研究对象,其中行玻璃体切除术患者50例,小梁切除术患者50例。美国麻醉医师协会分级Ⅰ～Ⅱ级,年龄16～80岁,体重35～80 kg。将研究对象分为两组,实验组(右美托咪定组)和对照组(安慰剂组),每组各50例,两种患者各25例。实验组患者手术开始前10min给予右美托咪定负荷剂量0.5μg/kg,输注时间大于10 min,之后以0.5μg/(kg*h)进行维持;对照组给予等体积的生理盐水。手术医生用2%利多卡因进行球周浸润麻醉时,两组患者均给予静脉注射半量芬氟合剂(芬太尼50μg +氟哌利多2.5mg)。记录手术开始前10mim(T_0)、开始时(T_1)、开始后10min(T_2)、开始后30min(T_3)、开始后60min(T_4)、手术结束时(T_5)两组患者的呼吸频率、心率、收缩压、舒张压、平均动脉压、VAS评分和Ramsay评分,同时记录术中合作程度、术后遗忘程度和术后不良反应。采用SPSS 13.0统计软件进行统计分析。
结果:
1.实验组和对照组患者的年龄、性别、体重、手术时间差异无统计学意义,两组研究对象具有可比性。
2. Ramsay评分在T_0时两组间的差异无统计学意义,而在T_1～T_5时差异显著,且实验组的镇静评分显著高于对照组。
3. VAS评分在T_0时两组间的差异无统计学意义,而在T_1～T_5时差异显著,且实验组镇痛评分显著低于对照组。
4. T_0时刻实验组和对照组患者的SBP无统计学差异,而HR、DBP、MAP差异显著,且实验组显著低于对照组;T_1时刻实验组和对照组的HR、DBP、MAP无统计学差异,而SBP差异显著,且实验组显著低于对照组;T_2～T_5时刻HR、SBP、DBP、MAP在两组间差异显著,且实验组均低于对照组。
5. RR在T_0时刻两组间的差异无统计学意义,而在T_1～T_5时刻差异显著,且实验组患者的RR显著低于对照组。
6.患者术中合作程度在实验组和对照组间差异无统计学意义。术后遗忘程度在两组之间的差异显著,具有统计学意义,且实验组中完全遗忘者所占的比例(68%)显著高于对照组(0%)。
7.恶心、呕吐、呼吸抑制、心动过缓、躁动和嗜睡的发生率在实验组和对照组间的差异不具有统计学意义。
结论:
1.在眼科局麻手术中应用右美托咪定,可为患者提供满意舒适的镇静,且不降低术中患者的合作程度。
2.右美托咪定具有镇痛作用,能够增加眼科局麻手术患者对疼痛的耐受性。
3.右美托咪定能够维持血流动力学的稳定。
4.右美托咪定能够消除眼科局麻手术患者对麻醉和手术操作等的不良记忆,具有一定的顺行性遗忘作用。
5.眼科局麻手术中右美托咪定的应用不会增加恶心、呕吐、呼吸抑制、心动过缓、躁动和嗜睡等不良反应的发生率。
Dexmedetomidine is a new type of high selectiveα_2-adrenergic receptor agonists, which has sedative, analgesic and anxiolytic effects, can maintain hemodynamic stability, has no respiratory depression, amnesia after surgery and son on. Therefore it has applications in many fields of clinical medicine, especially as an adjuvant in anesthesia, providing the anesthesiologist a new choice. However, there is little research about giving the dexmedetomidine in ophthalmic surgery.
Objective: Evaluate the effects of sedative, analgesic, maintaining hemodynamic stability and forgotten, when dexmedetomidine was applicated to patients in ophthalmic surgery under local anesthesia.
Methods: Select 100 patients who were undergoing ophthalmic surgery with local anesthesia as the research object, 50 patients with vitrectomy, 50 patients with trabeculectomy. All the patients were ASAⅠ-Ⅱ, aged 16-80 years, weight 35-80 kg, of Which 50 patients with vitrectomy and the other 50 ones with trabeculectomy. Patients were divided into two groups, the experimental group(dexmedetomidine group) and control group (placebo group). Each group has 50 patients. The patients of the experimental group before surgery 10 min were given dexmedetomidine loading dose of 0.5μg/kg, the infusion time is greater than 10 min, followed by 0.5μg /(kg·h) for maintenance; control group received an equal volume of physiological salt. When the surgeon with 2% lidocaine for peribulbar anesthesia, the two groups of patients were given intravenous injection of half the amount of fentany-droperidol mixture (fentanyl 50μg+droperidol 2.5mg). Routine monitoring and recording the respiratory rate (RR), heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), main arterial blood pressure(MAP), VAS score and Ramsay score of patients in each group at 10 min before surgery (T_0), the time of starting surgery(T_1), 10 min after the start of surgery(T_2), 30 min after the start of surgery(T_3), 60 min after the start of surgery(T_4) and at the end of surgery (T_5), at the same time, recording the level of cooperation between intraoperative, the degree of surgical forgotten and postoperative adverse. Use SPSS 13.0 statistical software for statistical processing.
Results:
1. The difference between experimental group and control group in age, gender, weight and operation tine was not statistically significant. The two group had comparability.
2. Ramsay score was not significantly different between two groups at T_0, while was at T_1～T_5. Furthermore, Ramsay score in experimental group was significantly higher than control group.
3. VAS score was not significantly different between two groups at T_0, while was at T_1～T_5. Furthermore, VAS score in experimental group was significantly lower than control group.
4. At the time of T_0, SBP was not significantly different between experimental group and control group, while HR, DBP and MAP were. Furthermore, HR, DBP and MAP in experimental group were significantly lower than control group. At the time of T_1, HR, DBP and MAP were not significantly different between two groups, while SBP was. Furthermore, SBP in experimental group was significantly lower than control group. At the time of T_1～T_5, HR, SBP, DBP and MAP were significantly different between two groups, and all of them in experimental group were significantly lower than control group.
5. RR was not significantly different between two groups at T_0, while was at T_1～T_5. Furthermore, RR in experimental group was significantly higher than control group.
6. Cooperation degree of patients was not significantly different between experimental group and control group during surgery. The degree of postoperative forgotten was significantly different between two groups, and the rate of completely forgotten in experimental group (68%) was statistically higher than control group (0%).
7. The number of cases of nausea, vomiting, respiratory depression, bradycardia, restlessness and drowsiness were not significantly different between experimental group and control group.
Conclusion:
1. The application of dexmedetomidine in ophthalmic surgery under local anesthesia could make the Ramsay score of experimental group significantly higher, with providing comfortable calm for patients and not decreasing the cooperation degree during surgery.
2. Dexmedetomidine had analgesic effect, which can increase tolerability to pain for patients with ophthalmic surgery under local anesthesia.
3. Dexmedetomidine could maintain hemodynamic stability.
4. Dexmedetomidine could eliminate poor memory appearing because of anesthesia and operation of surgery in ophthalmic surgery under local anesthesia. Therefore, dexmedetomodine had a certain line of the forgotten role.
5. The application of dexmedetomidine in ophthalmic surgery under local anesthesia will not produce nausea, vomiting, respiratory inhibition, bradycardia, restlessness and drowsiness.
引文
1.林志彬,金有豫.医用药理学基础[M]. 6版.北京:世界图书出版公司, 2008: 79-80.
2.刘东,于布为.右美托咪啶的药理和临床应用[J].国外医学麻醉与复苏分册, 1995, 16(4): 232-235.
3.裴皓.盐酸右美托咪定的药理作用与临床应用[J].医药导报, 2010, 29(12): 1603-1607.
4. KHAN ZP, FERGUSON CN, JON ES BM. Alpha-2 and imidazoline receptor agonists: their pharmacology and therapeutic role[J]. Anesthesia, 1999, 54: 146-165.
5. MURRELL JC, HELLEBREKERS LJ. Medetomidine anf dexmedetomidine: a review of cardiovascular effects and antinociceptive properties in the dog[J]. Vet Anaesth Analg, 2005, 32(3): 117-127.
6. YILDIZ M, TAVLAN A, TUNEER S, et al. Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation: perioperative haemodynamics and anaesthetic requirements[J]. Drugs RD, 2006, 7(1): 43-52.
7. SCHOLZ J, TONNER PH. Alpha2-adrenoceptor in anesthesia: a new paradigm[J]. Curr Opin Anesthnesiol, 2000, 13(4): 437-442.
8. ANTTILA M, PENTTILA J, HELMINEN A, et al. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects[J]. Br J Clin pharmacol, 2003, 56(6): 691-693.
9.宋威.右美托眯定的药理和临床研究[J].国外医学:合成药.生化药.制剂分册, 2001, 22(2): 106-107.
10. MAZE M, SCARFINI C, CAVALIERE F. New agents for sedation in the intensive care unit[J]. Crit Care Clin, 2001, 17(4): 881-897.
11. BYLUND DB. Pharmacological characteristics of alpha-2 adrenergic receptor subtypes[J]. Mol Pharmacol, 1992,42(1): 1-5.
12. BYLUND DB, EIKENBERG DC, HIEBLE JP, et al. International Union of pharmacology of adrenoceptors[J]. Pharmacol Rev, 1994, 46(2): 12-36.
13.冯征,王志萍.α2肾上腺素受体激动剂药及其临床应用进展[J].国外医学麻醉学与复苏分册, 1997, 18(5): 273-276.
14. LUNGER SZ, DUVAL N, MASSINGHAM R. Pharmacologic and therapeutic significance of alpha-adrenoceptor subtypes[J]. J Cardiovasc Pharmacol, 1985, 7(Suppl 8): S1-S8.
15. MANEHIKANTI L, BOSWELL MV, SINGH V, et al. Comprehensive evidence based guidelines for intervenetional techniques in the management of chronic spinal pain[J]. Pain Physician, 2009, 12(4): 699-802.
16.张洋,潘道波.盐酸右美托咪定的药理作用及其在全身麻醉中的应用[J].医学临床研究, 2011, 28(3): 535-537.
17.史曼,黄青青.右美托咪定的临床应用研究进展[J].现代医药卫生, 2011, 27(7): 1022-1024.
18. EISENACH JC. [Alpha] 2 agonists and analgesia[J]. Expopin Invest Drugs, 1994, 3: 1005-1010.
19. NELSON LE, LU J, GUO T, et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects[J]. Anesthesiology. 2003, 98(2): 428-436.
20. NACIF-COELHO C, CORREA-SALES C, CHANQ LL, et al. Perturbation of ion channel conductance alters the hypnotic response to the alpha 2-adrenergic agonist dexmedetomidine in the locus coeruleus of the rat[J]. Anesthesiology, 1994, 81(6): 1527-1534.
21. COULL JT, JONES ME, EGAN TD, et al. Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage[J]. 2004 , 22(1): 315-322.
22. BEKKER A, STURAITIS MK. Dexmedetomidine for neurological surgery[J]. Neurosurgery, 2005, 57: 1-10.
23. EISENACH JC, SHAFER SL, BUCKLN BA, et al. Pharmacokinetics and Pharmacodynamics of intraspinal dexmedetomidine in sheep[J]. Anesthesiology, 1994, 80(9): 1349-1359.
24. CONINEZ LI, HSU YW, SUM-PING ST, et al. Dexmedetomidine pharmacodynamics: part II: crossover comparison of the analgesic efkct of dexmedetomidine and remifentanilin healthy volunteers[J]. Anesthesiology, 2004, 101(4): 1077-1083.
25. ANGST MS, RAMASWAMY B, DAVIES MF, et al. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans[J]. Anesthesiology, 2004, 101(3): 744-752.
26. GURBET A, BASAGAN-MOGOL E, TURKER G, et al. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements[J]. Can J Anesth, 2006, 53(7):646-652.
27. BLOOR BC, WARD DS, BELLEVILLE, et al. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes[J]. Anesthesiology, 1992, 77(6): 1134-1142.
28. MAIER C, STEINBERG GK, SUN GH, et al. Neuroprotection by theα2–adrenoceptor agonist dexmedetomidine in a focal model of cerebral ischemia[J]. Anesthesiology, 1993, 79: 306-312.
29.COSAR M, ESER O, FIDAN H, et al. The neuroprotective effects of dexmedetomidine in the hippocampus of rabbits after subarachnoid hemorrhage[J]. Surgical Neurology, 2009, 71(1): 54-59.
30.MA D, HOSSAIN M, RAJAKUMARASWAMY N, et al. Dexmedetomidine produces its neuroprotective effect via theα2A -adrenoceptor subtype[J]. Eur J Pharmacol, 2004, 502: 87-97.
31 . MA D, RAJAKUMARASWAMY N, MAZE M. Alpha2-Adrenoceptor agonists: shedding light on neuroprotection[J]? Br Med Bull, 2005, 71(1): 77-92.
32. ZOMOW MH, FLEISCHER JE, SCHELLER MS, et al. Dexmedetomidine ,an alpha 2-adrenergic agonist, decrease cerebral blood flow in the isoflurane-anesthetized dog[J]. Anesth Analg, 1990, 70(6): 624-630.
33. DRUMMOND JC, DAO AV, ROTH DM, et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans[J]. Anesthesiology, 2008, 108(2): 225-232.
34. LOU YP, FRANCO-CERECEDA A, LUNDBERG JM. Variable alpha 2-adrenoceptor-mediated inhibition of brochoconstriction and peptide release upon activation of pulmonary afferents[J]. Eur J Pharmacol, 1992, 210(2): 173-181.
35. HALL JE, UHRICH TD, BARNEY JA, et al. Sedative, amnestic, and analgesic propertiesof small-dose dexmedetomidine infusions[J]. Anesth Analg, 2000, 90(3): 699-705.
36. EBERT TJ, HALL JE, BARNEY JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans[J]. Anesthesiology, 2000, 93(2): 382-394.
37. TOBIAS JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology[J]. Pediatric critical care medicine, 2007, 8(2): 115-131.
38. BELLEVILLE JP, WARD DS, BLOOR BC. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate[J]. Anesthesiology, 1992, 77: 1125-1133.
39. TALKE PO, LOBO E, BROWN R. Systemically administeredα2-agonist-induced peripheral vasoconstriction in humans[J]. Anesthesiology, 2003, 99(1):65-70.
40.梁飞,肖晓山.盐酸右美托咪定的临床药理及应用[J].现代医院, 2010, 10(5): 91-93.
41.李民,张利萍,吴新民.右美托咪啶在临床麻醉中应用的研究进展[J].中国临床药理学杂志, 23(6): 466-470.
42. SAGEN J, PROUDFIT HK. Evidence for pain modulation by pre- and postsynaptic noradrenergic receptors in the medulla oblongata[J]. Brain Res, 1985, 331(2): 285-293.
43.石佳,于钦军.右美托咪啶的药理作用及在重症监护病房中的应用[J].国际麻醉学与复苏杂志, 2007, 28(6): 540-543.
44. ROEKAERTS PM, PRINZEN FW, DE LANGES. Beneficial effects of dexmedetomidine on ischacmic myocardium of anesthetized dogs[J]. British Journal of Anaesthesia,, 1996, 77(3): 427-429.
45. WILLIGERS HM, PRINZEN FW, ROEKAERTS PM, et al. Dexmedetomidine decreases perioperative myocardial lactate release in dogs[J]. Anesth Analg, 2003, 96(3): 657-664.
46. OKADA H, KURITA T, MOCHIZUKI T, et al. The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts[J]. Resuscitation, 2007, 74(3): 538-545.
47. GUO H, TAKAHASHI S. The effects of dexmedetomidine on left ventricular function during hypoxia and reoxygenayion in isolated rat hearts[J]. Anesth Analg, 2005, 100(3): 629.
48. SANDERS RD, MAZE M. Alpha2-adrenoceptor agonists[J]. Curr Opin Investig Drugs, 2007, 8(1): 25-33.
49. TANIGUCHI T, KIDAN Y, KANAKURA H, et al. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats[J]. Crit Care Med, 2004, 32(6): 1322-1326.
50.庄心良,曾因明,陈伯銮.现代麻醉学[M].北京:人民卫生出版社, 2003, 9, 167.
51.徐爽.盐酸右美托咪定对围拔管期应激反应的影响[M]. 2010: 7.
52. POMPOSELLI J, BAXTER J, BABINEAU T, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients[J]. Parenter Enteral Nutr, 1998, 22: 77-81.
53. ULNPLERREZ GE, ISAACS SD, BAZARGAN N, et al. Hyperglycemia: an independent marker of inhospital mortality in patients with undiagnosed diabetea[J]. Clin Endocrinol Metab, 2002, 87: 978-982.
54. HOFER S, STEPPAN J, WAGNER T, et al. Central sympatholytics prolong survival in experimental sepsis[J]. Crit Care, 2009, 13(1): R11.
55. VENN RM, BRYANT A, HALL GM, et al. Effects of dexmedetomidine on adrenocortical function,and the cardiovascular,endocrine and inflammatory responses in postoperative patients needing sedation in the intensive care unit[J]Br J Anaesth, 2001, 86: 650-656.
56. KAMIBAYASHI T, MAZE M. Clinical uses of alpha 2-adrenergic agonists[J]. Anesthesiology, 2000, 93: 1345-1350.
57. KARHUVAARA S, KALLIO A, SALONEN M, et al. Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers[J]. British journal of clinical pharmacology, 1991, 31(2): 160-165.
58. DOUFAS AG, LIN CM, SULEMAN MI, et al. Dexmedetomidine and meperidine additively reduce the shivering threshold in humans[J]. Stroke. 2003, 34(5): 1218-1223.
59. JEAN MANTZ. Alpha2-adrenoceptor agonists: analgesia, sedation, anxiolysis, haemodynamics, respiratory function and weaning[J]. Best Practice & Research Clinical Anaesthesiology,2000, 14(2): 433-448.
60. RIKER RR, SHEHABI Y, BOKESCH PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial[J]. JAMA, 2009, 301(5): 489-99.
61. URBAN MK, WUKOVITS B, FLYNN E. Dexmedetomidine versus propofol for sedationof ventilated spinalpatients[J]. Anesthesiology, 2004, 101(3A): A158.
62. SCHMIDT MD, EMILIA A, VALINETTI MD, et al. Effects of preanesthetic administration of midazolam, clonidine, or dexmedetomidine on postoperative pain and anxiety in children[J]. Pediatric Anesthesia, 2007, 17(7): 667-674.
63.高建瓴,詹英,杨建平.右美托咪定辅助全身麻醉患者的镇静及全身麻醉药物的节俭作用[J].上海医学, 2010, 33(6): 525-527.
64.邹鑫,王世端,冯伟.右美托咪定2种剂量对靶控输注丙泊酚效应室浓度的影响[J].中国新药与临床杂志, 2010, 29(10): 778-782.
65. CHU KS, WANG FY, HSU HT. The effectiveness of dexmedetomidine infusion for sedating oral cancer patients undergoing awake fibreoptic nasal intubation[J]. Eur J Anaesthesiol, 2010,27(1):36-40.
66. JOOSTE EH, OHKAWA S, SUN LS. Fiberoptic intubation with dexmedetomidine in two children with spinal impingements[J]. Anesth Analgesia, 2005, 101(4): 1248.
67.何莉,余守章,阮祥才.右旋美托嘧啶对舒芬太尼—丙泊酚靶控输注效应的影响[J].国际麻醉学与复苏学杂志, 2008, 29(5): 391-395.
68.郝静,吴浩,马正良.右美托咪定对后腹腔镜手术患者术中血流动力学的影响[J].中国微创外科杂志, 2011, 11(3): 215-219.
69. KERDAWY H, GOUDA N, KAMAL H. Dexmedetomidine as anaesthtic adjunct for patients undergoing off-pump coromary artery bypass grafting[J]. Egypt J Anaesth, 2004, 20: 29.
70. ARD JL JR, BEKKER AY, DOYLE WK. Dexmedetomidine in awake craniotomy: a technical note[J]. Surg Neurol, 2005, 63(2): 114.
71.金震,文艳.右美托咪定对剖胸手术全麻苏醒期躁动的防治作用[J].淮海医药, 2011, 29(3): 252-253.
72.仇琳,严伟民,姜虹.右美托咪定用于困难气道患者苏醒期拔管时的镇静效果[J].中国口腔颌面外科杂志, 2011, 9(10): 51-55.
73.周玉梅,李璟,涂远艳,等.右美托咪定在气管内全身麻醉苏醒期拔管的应用[J].中国妇幼保健, 2010, 25(27): 4004-4006.
74. KAYA FN, YAVASCAOGLU B, TURKER G, et al. Intravenous dexmedetomidine, but not midazolam, prolongs bupivacaine spinal anesthesia[J]. Can J Anaesth. 2010, 57(1):39-45.
75.周俊,王汉兵,林文静,等.右美托咪啶对上肢手术患者罗哌卡因臂丛神经阻滞效果及上肢缺血再灌注损伤的影响[J].中华麻醉学杂志, 2011, 31(1): 84-87.
76. LIN TF, YEH FS, LIN FS, et al. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia[J]. Br. J. Anaesth, 2009, 102 (1): 117-122.
77. DAI HAYASHI, TAKAYUKI KUNISAWA, ATSUSHI KUROSAWA, et al. Effect of the initial loading dose of dexmedetomidine on hemodynamics in pediatric patients undering cardiac surgery[J]. Masui The Japanese journal of anesthesiology, 2010, 59(3): 362-365.
78. TOBISE F, TOYOSMIMA Y, KAWANA S. Effect of dexmeditomidine on hemodynamics in pediatric patients following cardiac surgery[J]. Masui The Japanese journal of anesthesiology, 2007, 56(4): 409-413.
79. QUARTILHO A, MATA HP, IBRAHIM MM, et al. Production of paradoxical sensory hypersensittivity by alpha 2-adrenoreceptor agonists[J]. Anesthesiology, 2004, 100(6): 1538-1544.
80.吴在德,吴肇汉,等.外科学[M]. 7版.北京:人民卫生出版社, 2008: 84-85.
81.李朝霞,姚晓霞.眼科局麻手术术前访视效果观察[J].实用护理杂志, 2003, 19(4): 38-39.
82. VENN M, NEWMAN J, GROUNDS M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit[J]. Intensive Care Med, 2003, 29: 201-207.
83. TOBIAS JD, BERKENBOSCH JW. Sedation during mechanical ventilation in iinfants and children dexmedetomidine versus midazolam[J]. South Med J, 2004, 97(3): 451-455.
84.方仲蓉,赵晓琴,王古岩.右美托咪定对冠状动脉旁路移植术患者麻醉诱导期BIS和血流动力学的影响[J].中国微创外科杂志, 2011, 11(2): 113-118.
85.曹蕾.盐酸右美托咪定在开胸手术中的临床应用研究[D].长春:吉林大学, 2011.
86.刘玲,纪风涛,刘付宁.右美托咪定对老年患者腰-硬联合麻醉的镇静效应[J].临床麻醉学杂志, 2011, 27(1): 49-51.
87.喻文立,李津源,杜洪印.小剂量右美托咪定局麻在疝修补书中的应用[J].山东医药, 2011, 51(17): 107-108.
88. CHEUNG CW, YING CL, CHIU WK. et al. A comparison of dexmedetomidine andmidazolam for sedation in third molar surgery[J]. Anaesthesia, 2007, 62: 1132-1138.
89.周其富,蒋宗明.右美托咪定监护麻醉在老年性白内障合并高血压患者眼科手术中的应用[J].中国临床药理学和治疗学, 2011, 16(7): 823-826.
90.姚玉笙,陈彦青,甘秀峰,等.右美托咪啶对胃癌根治术后吗啡病人自控静脉镇痛效果的影响[J].中华麻醉学杂志, 2010, 30(7): 826-828.
91.张红斌,王公明,孙连功.右美托咪啶对原发性高血压病人术后舒芬太尼自控静脉镇痛效果的影响[J].中华麻醉学杂志, 2011, 31(1): 44-46.
92.王萍,丛海涛,徐韶怡.右旋美托咪定联合舒芬太尼在术后静脉自控镇痛中的应用[J].实用医学杂志, 2011, 27(2): 290-292.
93.徐威,方浩,叶鹏程.右旋美托咪定在老年人腹腔镜胆囊切除术的超前镇痛作用[J].中国临床医学, 2011, 18(1): 92-94.
94.张加强,孟凡民,侯艳华,等.右旋美托咪啶对小儿七氟醚麻醉苏醒期躁动及血流动力学的影响[J].临床麻醉学杂志, 2010, 26(7): 627-628.
95.李煜,张永福,赖国忠,等.右美托咪定对腹腔镜手术围术期血儿茶酚胺及血流动力学的影响[J].中国微创外科杂志, 2011, 11(2): 119-122.
96. TALKE P, CHEN R, THOMAS B, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery[J]. Anessth Analg, 2000, 90(4): 834-839.
97. TEKIN M, KATI I, TOMAK Y, et al. Effect of dexmedetomidine IV on the duration of spinal anesthesia with prilocaine: a double-blind, prospective study in adult surgical patients[J]. Current Therapeutic Research, 2007, 68(5): 313-324.
98. FURST SR, WEINGER MB. Dexmedetomidine, a selective alpha2-agonist, dose not potentiate the cardiorespiratory depression of alfentanil in the rat[J]. Anesthesiology, 1990, 72(5): 882-888.
99.梁永新,古妙宁,王世端,等.右美托咪定和丙泊酚用于硬膜外麻醉下妇科手术患者镇静的比较[J].临床麻醉学杂志, 2011, 27(4): 376-378.
100.詹银周,张兴安,邵伟栋,等.右美托咪定在臂丛神经阻滞麻醉中的应用[J].中国新药与临床杂志, 2011, 30(4): 272-274.
101.朱新杰,马瑞,胡芳宝,等.右美托咪院对超声引导下罗嗽卡因臂丛神经阻带效果的影响[J].实用疼痛学杂志, 2011, 7(2): 102-105.
102.梁永新,古妙宁,王世端,等.硬膜外麻醉下妇科手术患者右美托咪啶和咪达唑仑镇静效果的比较[J].中华麻醉学, 2010, 30(7): 887-888.
2.刘东,于布为.右美托咪啶的药理和临床应用[J].国外医学麻醉与复苏分册, 1995, 16(4): 232-235.
3.裴皓.盐酸右美托咪定的药理作用与临床应用[J].医药导报, 2010, 29(12): 1603-1607.
4. KHAN ZP, FERGUSON CN, JON ES BM. Alpha-2 and imidazoline receptor agonists: their pharmacology and therapeutic role[J]. Anesthesia, 1999, 54: 146-165.
5. MURRELL JC, HELLEBREKERS LJ. Medetomidine anf dexmedetomidine: a review of cardiovascular effects and antinociceptive properties in the dog[J]. Vet Anaesth Analg, 2005, 32(3): 117-127.
6. YILDIZ M, TAVLAN A, TUNEER S, et al. Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation: perioperative haemodynamics and anaesthetic requirements[J]. Drugs RD, 2006, 7(1): 43-52.
7. SCHOLZ J, TONNER PH. Alpha2-adrenoceptor in anesthesia: a new paradigm[J]. Curr Opin Anesthnesiol, 2000, 13(4): 437-442.
8. ANTTILA M, PENTTILA J, HELMINEN A, et al. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects[J]. Br J Clin pharmacol, 2003, 56(6): 691-693.
9.宋威.右美托眯定的药理和临床研究[J].国外医学:合成药.生化药.制剂分册, 2001, 22(2): 106-107.
10. MAZE M, SCARFINI C, CAVALIERE F. New agents for sedation in the intensive care unit[J]. Crit Care Clin, 2001, 17(4): 881-897.
11. BYLUND DB. Pharmacological characteristics of alpha-2 adrenergic receptor subtypes[J]. Mol Pharmacol, 1992,42(1): 1-5.
12. BYLUND DB, EIKENBERG DC, HIEBLE JP, et al. International Union of pharmacology of adrenoceptors[J]. Pharmacol Rev, 1994, 46(2): 12-36.
13.冯征,王志萍.α2肾上腺素受体激动剂药及其临床应用进展[J].国外医学麻醉学与复苏分册, 1997, 18(5): 273-276.
14. LUNGER SZ, DUVAL N, MASSINGHAM R. Pharmacologic and therapeutic significance of alpha-adrenoceptor subtypes[J]. J Cardiovasc Pharmacol, 1985, 7(Suppl 8): S1-S8.
15. MANEHIKANTI L, BOSWELL MV, SINGH V, et al. Comprehensive evidence based guidelines for intervenetional techniques in the management of chronic spinal pain[J]. Pain Physician, 2009, 12(4): 699-802.
16.张洋,潘道波.盐酸右美托咪定的药理作用及其在全身麻醉中的应用[J].医学临床研究, 2011, 28(3): 535-537.
17.史曼,黄青青.右美托咪定的临床应用研究进展[J].现代医药卫生, 2011, 27(7): 1022-1024.
18. EISENACH JC. [Alpha] 2 agonists and analgesia[J]. Expopin Invest Drugs, 1994, 3: 1005-1010.
19. NELSON LE, LU J, GUO T, et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects[J]. Anesthesiology. 2003, 98(2): 428-436.
20. NACIF-COELHO C, CORREA-SALES C, CHANQ LL, et al. Perturbation of ion channel conductance alters the hypnotic response to the alpha 2-adrenergic agonist dexmedetomidine in the locus coeruleus of the rat[J]. Anesthesiology, 1994, 81(6): 1527-1534.
21. COULL JT, JONES ME, EGAN TD, et al. Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage[J]. 2004 , 22(1): 315-322.
22. BEKKER A, STURAITIS MK. Dexmedetomidine for neurological surgery[J]. Neurosurgery, 2005, 57: 1-10.
23. EISENACH JC, SHAFER SL, BUCKLN BA, et al. Pharmacokinetics and Pharmacodynamics of intraspinal dexmedetomidine in sheep[J]. Anesthesiology, 1994, 80(9): 1349-1359.
24. CONINEZ LI, HSU YW, SUM-PING ST, et al. Dexmedetomidine pharmacodynamics: part II: crossover comparison of the analgesic efkct of dexmedetomidine and remifentanilin healthy volunteers[J]. Anesthesiology, 2004, 101(4): 1077-1083.
25. ANGST MS, RAMASWAMY B, DAVIES MF, et al. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans[J]. Anesthesiology, 2004, 101(3): 744-752.
26. GURBET A, BASAGAN-MOGOL E, TURKER G, et al. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements[J]. Can J Anesth, 2006, 53(7):646-652.
27. BLOOR BC, WARD DS, BELLEVILLE, et al. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes[J]. Anesthesiology, 1992, 77(6): 1134-1142.
28. MAIER C, STEINBERG GK, SUN GH, et al. Neuroprotection by theα2–adrenoceptor agonist dexmedetomidine in a focal model of cerebral ischemia[J]. Anesthesiology, 1993, 79: 306-312.
29.COSAR M, ESER O, FIDAN H, et al. The neuroprotective effects of dexmedetomidine in the hippocampus of rabbits after subarachnoid hemorrhage[J]. Surgical Neurology, 2009, 71(1): 54-59.
30.MA D, HOSSAIN M, RAJAKUMARASWAMY N, et al. Dexmedetomidine produces its neuroprotective effect via theα2A -adrenoceptor subtype[J]. Eur J Pharmacol, 2004, 502: 87-97.
31 . MA D, RAJAKUMARASWAMY N, MAZE M. Alpha2-Adrenoceptor agonists: shedding light on neuroprotection[J]? Br Med Bull, 2005, 71(1): 77-92.
32. ZOMOW MH, FLEISCHER JE, SCHELLER MS, et al. Dexmedetomidine ,an alpha 2-adrenergic agonist, decrease cerebral blood flow in the isoflurane-anesthetized dog[J]. Anesth Analg, 1990, 70(6): 624-630.
33. DRUMMOND JC, DAO AV, ROTH DM, et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans[J]. Anesthesiology, 2008, 108(2): 225-232.
34. LOU YP, FRANCO-CERECEDA A, LUNDBERG JM. Variable alpha 2-adrenoceptor-mediated inhibition of brochoconstriction and peptide release upon activation of pulmonary afferents[J]. Eur J Pharmacol, 1992, 210(2): 173-181.
35. HALL JE, UHRICH TD, BARNEY JA, et al. Sedative, amnestic, and analgesic propertiesof small-dose dexmedetomidine infusions[J]. Anesth Analg, 2000, 90(3): 699-705.
36. EBERT TJ, HALL JE, BARNEY JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans[J]. Anesthesiology, 2000, 93(2): 382-394.
37. TOBIAS JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology[J]. Pediatric critical care medicine, 2007, 8(2): 115-131.
38. BELLEVILLE JP, WARD DS, BLOOR BC. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate[J]. Anesthesiology, 1992, 77: 1125-1133.
39. TALKE PO, LOBO E, BROWN R. Systemically administeredα2-agonist-induced peripheral vasoconstriction in humans[J]. Anesthesiology, 2003, 99(1):65-70.
40.梁飞,肖晓山.盐酸右美托咪定的临床药理及应用[J].现代医院, 2010, 10(5): 91-93.
41.李民,张利萍,吴新民.右美托咪啶在临床麻醉中应用的研究进展[J].中国临床药理学杂志, 23(6): 466-470.
42. SAGEN J, PROUDFIT HK. Evidence for pain modulation by pre- and postsynaptic noradrenergic receptors in the medulla oblongata[J]. Brain Res, 1985, 331(2): 285-293.
43.石佳,于钦军.右美托咪啶的药理作用及在重症监护病房中的应用[J].国际麻醉学与复苏杂志, 2007, 28(6): 540-543.
44. ROEKAERTS PM, PRINZEN FW, DE LANGES. Beneficial effects of dexmedetomidine on ischacmic myocardium of anesthetized dogs[J]. British Journal of Anaesthesia,, 1996, 77(3): 427-429.
45. WILLIGERS HM, PRINZEN FW, ROEKAERTS PM, et al. Dexmedetomidine decreases perioperative myocardial lactate release in dogs[J]. Anesth Analg, 2003, 96(3): 657-664.
46. OKADA H, KURITA T, MOCHIZUKI T, et al. The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts[J]. Resuscitation, 2007, 74(3): 538-545.
47. GUO H, TAKAHASHI S. The effects of dexmedetomidine on left ventricular function during hypoxia and reoxygenayion in isolated rat hearts[J]. Anesth Analg, 2005, 100(3): 629.
48. SANDERS RD, MAZE M. Alpha2-adrenoceptor agonists[J]. Curr Opin Investig Drugs, 2007, 8(1): 25-33.
49. TANIGUCHI T, KIDAN Y, KANAKURA H, et al. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats[J]. Crit Care Med, 2004, 32(6): 1322-1326.
50.庄心良,曾因明,陈伯銮.现代麻醉学[M].北京:人民卫生出版社, 2003, 9, 167.
51.徐爽.盐酸右美托咪定对围拔管期应激反应的影响[M]. 2010: 7.
52. POMPOSELLI J, BAXTER J, BABINEAU T, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients[J]. Parenter Enteral Nutr, 1998, 22: 77-81.
53. ULNPLERREZ GE, ISAACS SD, BAZARGAN N, et al. Hyperglycemia: an independent marker of inhospital mortality in patients with undiagnosed diabetea[J]. Clin Endocrinol Metab, 2002, 87: 978-982.
54. HOFER S, STEPPAN J, WAGNER T, et al. Central sympatholytics prolong survival in experimental sepsis[J]. Crit Care, 2009, 13(1): R11.
55. VENN RM, BRYANT A, HALL GM, et al. Effects of dexmedetomidine on adrenocortical function,and the cardiovascular,endocrine and inflammatory responses in postoperative patients needing sedation in the intensive care unit[J]Br J Anaesth, 2001, 86: 650-656.
56. KAMIBAYASHI T, MAZE M. Clinical uses of alpha 2-adrenergic agonists[J]. Anesthesiology, 2000, 93: 1345-1350.
57. KARHUVAARA S, KALLIO A, SALONEN M, et al. Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers[J]. British journal of clinical pharmacology, 1991, 31(2): 160-165.
58. DOUFAS AG, LIN CM, SULEMAN MI, et al. Dexmedetomidine and meperidine additively reduce the shivering threshold in humans[J]. Stroke. 2003, 34(5): 1218-1223.
59. JEAN MANTZ. Alpha2-adrenoceptor agonists: analgesia, sedation, anxiolysis, haemodynamics, respiratory function and weaning[J]. Best Practice & Research Clinical Anaesthesiology,2000, 14(2): 433-448.
60. RIKER RR, SHEHABI Y, BOKESCH PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial[J]. JAMA, 2009, 301(5): 489-99.
61. URBAN MK, WUKOVITS B, FLYNN E. Dexmedetomidine versus propofol for sedationof ventilated spinalpatients[J]. Anesthesiology, 2004, 101(3A): A158.
62. SCHMIDT MD, EMILIA A, VALINETTI MD, et al. Effects of preanesthetic administration of midazolam, clonidine, or dexmedetomidine on postoperative pain and anxiety in children[J]. Pediatric Anesthesia, 2007, 17(7): 667-674.
63.高建瓴,詹英,杨建平.右美托咪定辅助全身麻醉患者的镇静及全身麻醉药物的节俭作用[J].上海医学, 2010, 33(6): 525-527.
64.邹鑫,王世端,冯伟.右美托咪定2种剂量对靶控输注丙泊酚效应室浓度的影响[J].中国新药与临床杂志, 2010, 29(10): 778-782.
65. CHU KS, WANG FY, HSU HT. The effectiveness of dexmedetomidine infusion for sedating oral cancer patients undergoing awake fibreoptic nasal intubation[J]. Eur J Anaesthesiol, 2010,27(1):36-40.
66. JOOSTE EH, OHKAWA S, SUN LS. Fiberoptic intubation with dexmedetomidine in two children with spinal impingements[J]. Anesth Analgesia, 2005, 101(4): 1248.
67.何莉,余守章,阮祥才.右旋美托嘧啶对舒芬太尼—丙泊酚靶控输注效应的影响[J].国际麻醉学与复苏学杂志, 2008, 29(5): 391-395.
68.郝静,吴浩,马正良.右美托咪定对后腹腔镜手术患者术中血流动力学的影响[J].中国微创外科杂志, 2011, 11(3): 215-219.
69. KERDAWY H, GOUDA N, KAMAL H. Dexmedetomidine as anaesthtic adjunct for patients undergoing off-pump coromary artery bypass grafting[J]. Egypt J Anaesth, 2004, 20: 29.
70. ARD JL JR, BEKKER AY, DOYLE WK. Dexmedetomidine in awake craniotomy: a technical note[J]. Surg Neurol, 2005, 63(2): 114.
71.金震,文艳.右美托咪定对剖胸手术全麻苏醒期躁动的防治作用[J].淮海医药, 2011, 29(3): 252-253.
72.仇琳,严伟民,姜虹.右美托咪定用于困难气道患者苏醒期拔管时的镇静效果[J].中国口腔颌面外科杂志, 2011, 9(10): 51-55.
73.周玉梅,李璟,涂远艳,等.右美托咪定在气管内全身麻醉苏醒期拔管的应用[J].中国妇幼保健, 2010, 25(27): 4004-4006.
74. KAYA FN, YAVASCAOGLU B, TURKER G, et al. Intravenous dexmedetomidine, but not midazolam, prolongs bupivacaine spinal anesthesia[J]. Can J Anaesth. 2010, 57(1):39-45.
75.周俊,王汉兵,林文静,等.右美托咪啶对上肢手术患者罗哌卡因臂丛神经阻滞效果及上肢缺血再灌注损伤的影响[J].中华麻醉学杂志, 2011, 31(1): 84-87.
76. LIN TF, YEH FS, LIN FS, et al. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia[J]. Br. J. Anaesth, 2009, 102 (1): 117-122.
77. DAI HAYASHI, TAKAYUKI KUNISAWA, ATSUSHI KUROSAWA, et al. Effect of the initial loading dose of dexmedetomidine on hemodynamics in pediatric patients undering cardiac surgery[J]. Masui The Japanese journal of anesthesiology, 2010, 59(3): 362-365.
78. TOBISE F, TOYOSMIMA Y, KAWANA S. Effect of dexmeditomidine on hemodynamics in pediatric patients following cardiac surgery[J]. Masui The Japanese journal of anesthesiology, 2007, 56(4): 409-413.
79. QUARTILHO A, MATA HP, IBRAHIM MM, et al. Production of paradoxical sensory hypersensittivity by alpha 2-adrenoreceptor agonists[J]. Anesthesiology, 2004, 100(6): 1538-1544.
80.吴在德,吴肇汉,等.外科学[M]. 7版.北京:人民卫生出版社, 2008: 84-85.
81.李朝霞,姚晓霞.眼科局麻手术术前访视效果观察[J].实用护理杂志, 2003, 19(4): 38-39.
82. VENN M, NEWMAN J, GROUNDS M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit[J]. Intensive Care Med, 2003, 29: 201-207.
83. TOBIAS JD, BERKENBOSCH JW. Sedation during mechanical ventilation in iinfants and children dexmedetomidine versus midazolam[J]. South Med J, 2004, 97(3): 451-455.
84.方仲蓉,赵晓琴,王古岩.右美托咪定对冠状动脉旁路移植术患者麻醉诱导期BIS和血流动力学的影响[J].中国微创外科杂志, 2011, 11(2): 113-118.
85.曹蕾.盐酸右美托咪定在开胸手术中的临床应用研究[D].长春:吉林大学, 2011.
86.刘玲,纪风涛,刘付宁.右美托咪定对老年患者腰-硬联合麻醉的镇静效应[J].临床麻醉学杂志, 2011, 27(1): 49-51.
87.喻文立,李津源,杜洪印.小剂量右美托咪定局麻在疝修补书中的应用[J].山东医药, 2011, 51(17): 107-108.
88. CHEUNG CW, YING CL, CHIU WK. et al. A comparison of dexmedetomidine andmidazolam for sedation in third molar surgery[J]. Anaesthesia, 2007, 62: 1132-1138.
89.周其富,蒋宗明.右美托咪定监护麻醉在老年性白内障合并高血压患者眼科手术中的应用[J].中国临床药理学和治疗学, 2011, 16(7): 823-826.
90.姚玉笙,陈彦青,甘秀峰,等.右美托咪啶对胃癌根治术后吗啡病人自控静脉镇痛效果的影响[J].中华麻醉学杂志, 2010, 30(7): 826-828.
91.张红斌,王公明,孙连功.右美托咪啶对原发性高血压病人术后舒芬太尼自控静脉镇痛效果的影响[J].中华麻醉学杂志, 2011, 31(1): 44-46.
92.王萍,丛海涛,徐韶怡.右旋美托咪定联合舒芬太尼在术后静脉自控镇痛中的应用[J].实用医学杂志, 2011, 27(2): 290-292.
93.徐威,方浩,叶鹏程.右旋美托咪定在老年人腹腔镜胆囊切除术的超前镇痛作用[J].中国临床医学, 2011, 18(1): 92-94.
94.张加强,孟凡民,侯艳华,等.右旋美托咪啶对小儿七氟醚麻醉苏醒期躁动及血流动力学的影响[J].临床麻醉学杂志, 2010, 26(7): 627-628.
95.李煜,张永福,赖国忠,等.右美托咪定对腹腔镜手术围术期血儿茶酚胺及血流动力学的影响[J].中国微创外科杂志, 2011, 11(2): 119-122.
96. TALKE P, CHEN R, THOMAS B, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery[J]. Anessth Analg, 2000, 90(4): 834-839.
97. TEKIN M, KATI I, TOMAK Y, et al. Effect of dexmedetomidine IV on the duration of spinal anesthesia with prilocaine: a double-blind, prospective study in adult surgical patients[J]. Current Therapeutic Research, 2007, 68(5): 313-324.
98. FURST SR, WEINGER MB. Dexmedetomidine, a selective alpha2-agonist, dose not potentiate the cardiorespiratory depression of alfentanil in the rat[J]. Anesthesiology, 1990, 72(5): 882-888.
99.梁永新,古妙宁,王世端,等.右美托咪定和丙泊酚用于硬膜外麻醉下妇科手术患者镇静的比较[J].临床麻醉学杂志, 2011, 27(4): 376-378.
100.詹银周,张兴安,邵伟栋,等.右美托咪定在臂丛神经阻滞麻醉中的应用[J].中国新药与临床杂志, 2011, 30(4): 272-274.
101.朱新杰,马瑞,胡芳宝,等.右美托咪院对超声引导下罗嗽卡因臂丛神经阻带效果的影响[J].实用疼痛学杂志, 2011, 7(2): 102-105.
102.梁永新,古妙宁,王世端,等.硬膜外麻醉下妇科手术患者右美托咪啶和咪达唑仑镇静效果的比较[J].中华麻醉学, 2010, 30(7): 887-888.